LEP and metabolic dysfunction-associated steatohepatitis: These data demonstrated novel molecular events for leptin inhibition of PPARγ1 expression in HSCs and thus might have potential implications for clarifying the detailed mechanisms underlying liver fibrosis in diseases in which circulating leptin levels are elevated such as in non‐alcoholic steatohepatitis in obese patients.